

IN THE CLAIMS:

Please cancel non-elected claims ~~3, 5, 8~~ through ~~10, 12, 13, and 16 through 18~~ without prejudice or disclaimer.

B B'

1. (Twice amended) A peptide which comprises:
at least part of the amino acid sequence of SEQ. ID. [No. 1] NO. 9 wherein an original amino acid at position 2 or 8 is substituted with a replacement amino acid and wherein said peptide is immunogenic with lymphocytes directed against metastatic melanomas.

B B' 2 3 4
B 4

4. (Twice amended) The peptide according to Claim 1, wherein said peptide comprises the amino acid sequence of SEQ. ID. NO. [2] 1.

Claim 6, line 1, after "A", please insert -vaccine-.

B B' 3

11. (Twice amended) A method for isolating melanoma antigen reactive tumor infiltrating lymphocytes, said method comprising the steps of:

- a. taking a sample of a melanoma from a [patient]subject;
- b. isolating tumor infiltrating lymphocytes from said sample;
- c. reacting said tumor infiltrating lymphocytes with a peptide [of claim 1]comprising at least part of the amino acid sequence of SEQ. ID. NO. 9 wherein an original amino acid at position 2 or 8 of SEQ. ID. NO. 9 is substituted with a replacement amino acid and wherein said peptide is immunogenic with lymphocytes directed against metastatic melanomas to form an antigen-lymphocyte complex; and
- d. recovering lymphocytes from said antigen-lymphocyte complex [whereby isolated]thus isolating melanoma antigen reactive tumor infiltrating lymphocytes [are obtained].

Please add the following claims:

20. The peptide of claim 1 wherein said original amino acid at position 8, glutamine, is substituted by replacement amino acid, alanine, and said original amino acid at position 2, threonine, is substituted by a replacement amino acid selected from the group consisting of isoleucine, leucine and valine.

21. ~~The vaccine of claim 6 wherein the peptide has an alanine at position 8 or is an epitope of said peptide that is immunogenic with lymphocytes directed against metastatic melanomas.~~

On b
B X
22. The vaccine of claim 6 wherein said peptide has a replacement amino acid at position 2, said replacement amino acid selected from the group consisting of isoleucine, leucine, and valine or is an epitope of said peptide that is immunogenic with lymphocytes directed against metastatic melanomas.

A
23. The vaccine of claim 6, wherein said peptide comprises the amino acid sequence of SEQ. ID. NO. 1 or is an epitope of said peptide that is immunogenic with lymphocytes directed against metastatic melanomas.

24. The vaccine of claim 21 further comprising a pharmaceutically acceptable carrier or diluent.

25. The vaccine of claim 22 further comprising a pharmaceutically acceptable carrier or diluent.

26. The vaccine of claim 23 further comprising a pharmaceutically acceptable carrier or diluent.

27. The method according to claim 11 wherein said peptide has an alanine at position 8.